The NeuStemGen consortium create a collaborative network of Polish research organizations and industrial participants, with the necessary cross-disciplinary expertise in clinical and experimental neurology and ophthalmology, genetics and bioinformatics. Here we propose a practical approach with special emphasis on translating basic mechanisms into clinical applications that will provide health benefits for our aging population with great imapct on
personalized medicine development. Especially, the goal of this proposal is to carry out joint research on molecular and cellular networks that are commonly disrupted in neurodegenerative disorders (e.g.: age-related macular degeneration) , in order to identify novel biomarkers, which may serve as diagnostic, prophylactic and patient-tailored prevention

Concurrently, the NeuStemGen will focus on innovative approaches to potentiate the neuroprotective potential of different types of stem/progenitor cells in order to optimize their clinical implementation. This in turn will provide validated targets for development of novel therapeutics ready to use in population of Polish patients with progressive, currently incurable neurodegenerative diseases, e.g.: amyotrophic lateral sclerosis, severe brain injury and retinal


Coordinator of NeuStemGen consortium – Pomeranian Medical University in Szczecin /PUM/


  • Medical University of Silesia / MUS/
  • Genomed Joint Stock Company / Genomed JSC/
  • Mossakowski Medical Research Centre Polish Academy of Sciences /MMRC/
  • Polish-Japanese Institute of Information Technology / PJIIT/
  • West Pomeranian University of Technology /WPUT/
  • University of Warmia and Mazury in Olsztyn /UWM/
  • “AKOGO” of Ewa Błaszczyk Foundation /”AKOGO” Foundation/

The planned duration of the project is 36 months
Date of realization: 1 September 2014 – 31 August 2017
Project budget: PLN 45,564,696.00, including PLN 19 572 980,00 eligible.
Value of grant: 96,69%.
Project No.: STRATEGMED1/234261/2/NCBR/2014

Research chase:

Task 1
Epigenetic/hypoxiadependent modifications of different human stem cell populations for enhancement of their neuroprotective functions
Partners: PUM, MMRC

Task 2
Stem cell encapsulation and insertion into bioscaffolds to provide enhanced cell survival or biodistribution in neurodegenerating micro environment
Partners: PUM, MMRC

Task 3
Preclinical studies for optimizing SC therapies of retinal degeneration in animal models.
Partners: PUM

Task 4
Preclinical studies for optimizing SC therapies of CNS neurodegeneration in Animals models
Partners: MMRC

Task 5
Development of innovative clinical stem-cell therapies for retinal degeneration
Partners: PUM

Task 6
Development of innovative stem-cell therapies for CNS neurodegeneration
Partners: PUM, UWM, “AKOGO” Foundation

Task 7
Development and characterization of new genetic tests for detection of predisposition to retinal degeneration in Polish population

Task 8
Development and characterization of new biomarkers for early detection of retinal degeneration in Polish population
Partners: PUM, MUS

Task 9
Computer Aided and Image Guided Support for the Prevention and Assessment of Neurodegenerative Diseases
Partners: PJIIT, WPUT

Preparation for implementation chase

Task 10
Innovative technology transfer and quality control activities
Partners: PUM, MUS, Genomed JSC, MMRC, PJIIT, WPUT, UWM